BR112022011372A2 - Inibidores de interação de proteína a de replicação (rpa)-dna - Google Patents
Inibidores de interação de proteína a de replicação (rpa)-dnaInfo
- Publication number
- BR112022011372A2 BR112022011372A2 BR112022011372A BR112022011372A BR112022011372A2 BR 112022011372 A2 BR112022011372 A2 BR 112022011372A2 BR 112022011372 A BR112022011372 A BR 112022011372A BR 112022011372 A BR112022011372 A BR 112022011372A BR 112022011372 A2 BR112022011372 A2 BR 112022011372A2
- Authority
- BR
- Brazil
- Prior art keywords
- rpa
- replication protein
- dna interaction
- interaction inhibitors
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946100P | 2019-12-10 | 2019-12-10 | |
| PCT/US2020/064191 WO2021119242A1 (en) | 2019-12-10 | 2020-12-10 | Replication protein a (rpa)-dna interaction inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011372A2 true BR112022011372A2 (pt) | 2022-08-23 |
Family
ID=76330773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011372A BR112022011372A2 (pt) | 2019-12-10 | 2020-12-10 | Inibidores de interação de proteína a de replicação (rpa)-dna |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12486246B2 (https=) |
| EP (1) | EP4073055A4 (https=) |
| JP (1) | JP7677646B2 (https=) |
| BR (1) | BR112022011372A2 (https=) |
| CA (1) | CA3162280A1 (https=) |
| WO (1) | WO2021119242A1 (https=) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| EP2402323A3 (en) * | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| EP1905762A1 (en) | 2005-05-30 | 2008-04-02 | Genecare Research Institute Co., Ltd | Pyrazolone derivative |
| US20100055116A1 (en) | 2006-04-13 | 2010-03-04 | Liou Hsiou-Chi | Methods and Compositions for Targeting c-Rel |
| WO2008045663A2 (en) * | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
| MY150697A (en) | 2007-04-10 | 2014-02-28 | Exelixis Inc | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha |
| WO2008148747A2 (en) | 2007-06-08 | 2008-12-11 | University Of Copenhagen | Pdz domain modulators |
| US8476458B2 (en) | 2007-06-21 | 2013-07-02 | The Wistar Institute | Methods and compositions for modulating P300/CBP activity |
| HRP20161004T1 (hr) | 2007-09-27 | 2016-10-21 | Dow Agrosciences Llc | Tehnološki konstruirani proteini cinkovi prsti koji imaju kao cilj gene za sintazu 5-enolpiruvilshikimat-3-fosfata |
| WO2009145829A1 (en) | 2008-04-01 | 2009-12-03 | University Of Massachusetts | Type iii secretion inhibitors, analogs and uses thereof |
| WO2009146179A1 (en) | 2008-04-15 | 2009-12-03 | University Of Iowa Research Foundation | Zinc finger nuclease for the cftr gene and methods of use thereof |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| CA2825680C (en) | 2010-02-05 | 2019-12-03 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
| WO2012037573A1 (en) | 2010-09-17 | 2012-03-22 | Indiana University Research And Technology Corporation | Small molecule inhibitors of replication protein a that also act synergistically with cisplatin |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| JP6482546B2 (ja) | 2013-07-19 | 2019-03-13 | ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ | 二重対立遺伝子ノックアウトを生成するための方法および組成物 |
| WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
| ITMI20131410A1 (it) | 2013-08-26 | 2015-02-27 | Univ Degli Studi Modena E Reggio Emilia | Composti e composizioni per l'uso nella inibizione dell' interazione lbc-rhoa |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| WO2016077752A2 (en) * | 2014-11-13 | 2016-05-19 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
| WO2017205503A1 (en) | 2016-05-24 | 2017-11-30 | Indiana University Research And Technology Corporation | Ku inhibitors and their use |
| CA3075734A1 (en) | 2017-09-19 | 2019-03-28 | Indiana University Research And Technology Corporation | Xpa inhibitor compounds and their use |
-
2020
- 2020-12-10 BR BR112022011372A patent/BR112022011372A2/pt unknown
- 2020-12-10 CA CA3162280A patent/CA3162280A1/en active Pending
- 2020-12-10 US US17/782,876 patent/US12486246B2/en active Active
- 2020-12-10 EP EP20897908.8A patent/EP4073055A4/en active Pending
- 2020-12-10 JP JP2022535116A patent/JP7677646B2/ja active Active
- 2020-12-10 WO PCT/US2020/064191 patent/WO2021119242A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US12486246B2 (en) | 2025-12-02 |
| CA3162280A1 (en) | 2021-06-17 |
| JP7677646B2 (ja) | 2025-05-15 |
| EP4073055A1 (en) | 2022-10-19 |
| US20230056729A1 (en) | 2023-02-23 |
| WO2021119242A1 (en) | 2021-06-17 |
| JP2023505690A (ja) | 2023-02-10 |
| EP4073055A4 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022008535A2 (pt) | Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112021023359A2 (pt) | Inibidores de g12c de kras e usos dos mesmos | |
| BR112022008534A2 (pt) | Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| BR112018008918A8 (pt) | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112017023904A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017002403A2 (pt) | formas de cristais de inibidores de glutaminase | |
| BR112018068956A2 (pt) | derivados do composto indol substituídos como inibidores da replicação viral da dengue | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112018069601A2 (pt) | derivados de indolina substituídos como inibidores da replicação viral da dengue | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
| BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
| BR112022003959A2 (pt) | Métodos para tratamento de epilepsia | |
| BR112017015123A2 (pt) | derivados de indol como inibidores da replicação viral do dengue | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| BR112021018254A2 (pt) | Derivados de nicorandil | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| BR112017022958A2 (pt) | métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |